Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy

Published:2018-04-19 Issue:6 Volume:7 Page:2405-2414
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Pataer Apar¹^ORCID,Shao Ruping¹,Correa Arlene M.¹,Behrens Carmen²,Roth Jack A.¹,Vaporciyan Ara A.¹,Wistuba Ignacio I.³,Swisher Stephen G.¹

Affiliation:

1. Department of Thoracic and Cardiovascular Surgery; The University of Texas MD Anderson Cancer Center; Houston Texas

2. Department of Thoracic/Head and Neck Medical Oncology; The University of Texas MD Anderson Cancer Center; Houston Texas

3. Department of Translational Molecular Pathology; The University of Texas MD Anderson Cancer Center; Houston Texas

Funder

National Institutes of Health

Homer Flower Research Fund

Charles Rogers Gene Therapy Fund

Margaret Wiess Elkins Endowed Research Fund

Flora and Stuart Mason Lung Cancer Research Fund

Phalan Thoracic Gene Therapy Fund

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Reference34 articles.

1. Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer;Rosell;Semin. Oncol.,2001

2. The role of neoadjuvant trials in drug development for solid tumors;Funt;Clin. Cancer Res.,2016

3. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint;Hellmann;Lancet Oncol.,2014

4. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy;Pataer;J. Thorac. Oncol.,2012

5. Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy;William;J. Thorac. Oncol.,2013

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RAD51 is a poor prognostic marker and a potential therapeutic target for oral squamous cell carcinoma;Cancer Cell International;2023-10-05

2. Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer;Lung Cancer;2023-09

3. Predictive signature of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer integrating mRNA expression, taxonomic subtypes, and clinicopathological features;Frontiers in Oncology;2023-08-03

4. Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy;JTO Clinical and Research Reports;2022-11

5. A Pan-Cancer Analysis of the Oncogenic Roles of RAD51 in Human Tumors;Advanced Gut & Microbiome Research;2022-09-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3